This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ReVision Therapeutics, Inc.
Drug Names(s): RT-101, ST-602
Description: Fenretinide is a synthetic analog of retinoic acid (RA), that acts as a vitamin A binding protein antagonist.
Based on preclinical evidence, it is believed to halt the accumulation of retinol (vitamin A) toxins through affinity for retinol-binding protein. It is also believed to slow the formation and accumulation of toxic byproducts thought to be responsible for vision loss in conditions such as geographic atrophy.
Apoptosis in response to fenretinide treatment primarily occurs by a receptor-independent mechanism, which is accompanied by increases in signaling molecules, e.g., ceramide, and cysteine-dependent aspartate-directed proteases, termed caspases, including execution caspase-3.
Deal Structure: Fenretinide was originally developed by Sytera.
In August 2006, Sirion Therapeutics announced that it completed a merger with Sytera. The newly merged company was named Sirion Therapeutics.
In March 2010, ReVision was spun-off from Sirion and acquired the rights to Fenretinide and Sirion's other opthalmogic drugs.
Fenretinide (ReVision) News
Scrip Sirion Therapeutics Inc.
Additional information available to subscribers only: